Analyst Ratings for SAB Biotherapeutics (SABS)
SABS Rating Summary
SABS Price Target Summary
- Highest: $15.00 (Guggenheim)
- Lowest: $7.00 (Leerink Partners)
- Average: $10.14
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$10.14 (+167.6%)
* Over Last 12-Mos
Rating Score: 9.1 / 10
Percentile Rank: 90%
Avg. $ Target:
$10.14 (+167.6%)
* Over Last 12-Mos
Rating Score: 9.1 / 10
Percentile Rank: 90%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/7/2026 | Argus | N/A | New Coverage | Buy (N/A) |
7.00 (N/A) |
3.62 (3.79) |
4.7% | Details |
| 1/7/2026 | UBS | Michael Yee | New Coverage | Buy (N/A) |
7.00 (N/A) |
3.74 (3.79) |
1.34% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
